- Home
- AGIO
as 10-04-2024 4:00pm EST
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.4B | IPO Year: | 2013 |
| Target Price: | $52.50 | AVG Volume (30 days): | 585.1K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.80 - $53.29 | Next Earning Date: | 10-31-2024 |
| Revenue: | $31,306,000 | Revenue Growth: | 55.39% |
| Revenue Growth (this year): | 44.8% | Revenue Growth (next year): | 174.95% |
Stock Insider Trading Activity of Agios Pharmaceuticals Inc. (AGIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Goff Brian | AGIO | Chief Executive Officer | Aug 8 '24 | Sell | $42.75 | 11,091 | $474,140.25 | 78,792 |
Latest Agios Pharmaceuticals Inc. News
AGIO Breaking Stock News: Dive into AGIO Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
Agios Pharmaceuticals' Shares Fall After Downgrade From Leerink Partners
Zacks
8 days ago
Do Options Traders Know Something About Agios (AGIO) Stock We Don't?
MT Newswires
8 days ago
Leerink Partners Downgrades Agios Pharmaceuticals to Market Perform From Outperform, Price Target is $56
Investor's Business Daily
9 days ago
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Insider Monkey
18 days ago
Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results
Simply Wall St.
21 days ago
Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
Zacks
23 days ago
FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer
Pharmaceutical Technology
23 days ago
Agios Pharmaceuticals’ tebapivat gains FDA orphan drug designation
Compare AGIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGIO Agios Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.